Epitomee Medical Ltd (EPIT) - Total Liabilities
Based on the latest financial reports, Epitomee Medical Ltd (EPIT) has total liabilities worth ILA6.32 Million ILA (≈ $16.95K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Epitomee Medical Ltd (EPIT) equity growth momentum to track the company's year-over-year net asset growth rate.
Epitomee Medical Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Epitomee Medical Ltd's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Epitomee Medical Ltd to measure how efficiently the company converts operating cash flow to free cash.
Epitomee Medical Ltd Competitors by Total Liabilities
The table below lists competitors of Epitomee Medical Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renovaro Biosciences Inc
NASDAQ:RENB
|
USA | $29.58 Million |
|
China Crystal New Material
KQ:900250
|
Korea | ₩25.79 Billion |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
Thailand | ฿350.88 Million |
|
Andromeda Metals Ltd
AU:ADN
|
Australia | AU$2.27 Million |
|
CompuLab Ltd
TA:CLAB
|
Israel | ILA24.65 Million |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
Vietnam | ₫3.22 Trillion |
|
ilShinbiobase Co. Ltd
KQ:068330
|
Korea | ₩7.33 Billion |
|
Black Dragon Gold Corp
AU:BDG
|
Australia | AU$2.85 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Epitomee Medical Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EPIT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Epitomee Medical Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Epitomee Medical Ltd (2018–2024)
The table below shows the annual total liabilities of Epitomee Medical Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA6.26 Million ≈ $16.79K |
+14.57% |
| 2023-12-31 | ILA5.46 Million ≈ $14.65K |
-65.32% |
| 2022-12-31 | ILA15.76 Million ≈ $42.24K |
+23.82% |
| 2021-12-31 | ILA12.73 Million ≈ $34.12K |
-26.63% |
| 2020-12-31 | ILA17.34 Million ≈ $46.50K |
+2084.51% |
| 2019-12-31 | ILA794.00K ≈ $2.13K |
+1.79% |
| 2018-12-31 | ILA780.00K ≈ $2.09K |
-- |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.